Trial Profile
A first in human clinical trial of coronavirus neutralisng antibodies
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 03 Apr 2020
At a glance
- Drugs Coronavirus neutralising antibodies 3rd Peoples Hospital of Shenzhen/Brii Biosciences/Tsinghua University (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man
Most Recent Events
- 03 Apr 2020 New trial record
- 31 Mar 2020 According to a Tsinghua University media release, this study is planned for third quarter this year.
Trial Overview
Purpose
This study will evaluate coronavirus neutralisng antibodies for the treatment and prevention of COVID-19 infections.
Diseases Treated
| Indication | Qualifiers | Patient Segments |
|---|---|---|
| COVID 2019 infections | prevention, treatment | - |
Subjects
- Subject Type patients
- Sex not stated
Trial Details
Organisations
- Affiliations Brii Biosciences
Trial Dates
-
Initiation Dates
Planned : 01 Jul 2020
Other Details
- Design prospective
- Phase of Trial Phase I
- Location Unknown
- Focus Adverse reactions; First in man
Interventions
| Drugs | Route | Formulation | Target |
|---|---|---|---|
|
Coronavirus neutralising antibodies 3rd Peoples Hospital of Shenzhen/Brii Biosciences/Tsinghua University Primary Drug
|
Parenteral |
-
|
-
|
Coronavirus neutralisng antibodies
Trial History
| Event Date | Event Type | Comment |
|---|---|---|
| 03 Apr 2020 | New trial record | New trial record Updated 03 Apr 2020 |
| 31 Mar 2020 | Other trial event | According to a Tsinghua University media release, this study is planned for third quarter this year. Updated 03 Apr 2020 |
References
-
Tsinghua University. Tsinghua University, 3rd Peoples Hospital of Shenzhen and Brii Biosciences Establish Partnership to Develop Neutralizing Antibodies Against COVID-19. Media-Rel 2020;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG